title: [Benign prostatic hyperplasia: medical therapy].
abstract: Primary aims of the medical therapy for BPH are improvement of subjective symptoms and quality of life as well as the prevention of long-term complications such as acute urinary retention and renal failure. Secondary goal is inhibition of disease progression. The medical therapy should be tailored to each patient according to the individual complaints and risk of progression. Plant extracts, alpha-blockers and 5-alpha reductase inhibitors represent the most common prescribed substances. Recent data suggest beneficial effects for the use of antimuscarinic agents and phosphodiesterase type 5 inhibitors.
authors.affiliation: Klinik und Poliklinik für Urologie, Klinikum Grosshadern, Ludwig-Maximilians-Universität München. boris.schlenker@med.uni-muenchen.de
authors.forename: B
authors.initials: B
authors.lastname: Schlenker
authors.forename: C
authors.initials: C
authors.lastname: Gratzke
authors.forename: P
authors.initials: P
authors.lastname: Weidlich
authors.forename: M
authors.initials: M
authors.lastname: Seitz
authors.forename: O
authors.initials: O
authors.lastname: Reich
authors.forename: C G
authors.initials: CG
authors.lastname: Stief
mesh_terms: D013741:3-Oxo-5-alpha-Steroid 4-Dehydrogenase / Q000187:drug effects; D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D000465:Algorithms; D001378:Azasteroids / Q000008:administration & dosage / Q000627:therapeutic use; D018450:Disease Progression; D017292:Doxazosin / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D000068538:Dutasteride; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D018120:Finasteride / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D018727:Muscarinic Antagonists / Q000627:therapeutic use; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use; D008517:Phytotherapy; D010936:Plant Extracts / Q000008:administration & dosage / Q000627:therapeutic use; D011470:Prostatic Hyperplasia / Q000150:complications / Q000188:drug therapy*; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000317:Adrenergic alpha-Antagonists; D001378:Azasteroids; D004791:Enzyme Inhibitors; D018727:Muscarinic Antagonists; D010726:Phosphodiesterase Inhibitors; D010936:Plant Extracts; D018120:Finasteride; D013741:3-Oxo-5-alpha-Steroid 4-Dehydrogenase; D017292:Doxazosin; D000068538:Dutasteride